Nucleoside analogues modified in heteroeyclic bases or sugar moieties were screened for their ability of counteracting the bacteriostatic effect of showdomycin in E. colio Pyrimidine ribonucleosides or 2 -deoxyribonucleosides substituted at the position 5 wijh halogen^atom, methyl or hydroxyl group, 2 -fluoro-, 2 -chloro-2 -deoxyuridme and its 5-methyl homologue, N^-dimethylcytidine and N*-acetylcytidine, isoeytidine, l-Tp-D-ribofuranosyl)-4-aminopyrimidine-6-one, isoguanosine, purine riboside, the N°-and 8-substituted derivatives of adenosine, were a l l effective. With the exception of 5-hydroxyuridine, all these compounds were non-toxic in E. c o l i . The same group of compounds was shown to inhibit competitively the phosphorolysis of 2 -deoxythymidine in whole c e l l s , being inactive in cell-free extracts. The analogues apparently compete for a common nucleoside-binding site at the surface of the c e l l s . Showdomycin i t s e l f does not cause any irreversible inactivation of nucleoside-binding s i t e s .
INTRODUCTION

The b a c t e r i o s t a t i c a c t i v i t y of the a n t i b i o t i c showdomycin i s dependent on i t s uptake mediated by n u c l e o s i d e -t r a n s p o r t i n g system. Mutants d e f i c i e n t i n a component of t h i s system become
measuring the i n c o r p o r a t i o n of •* P t h e TRIS-glucose medium was u s e d , c o n t a i n i n g 41.5/UM P . . 6 Showdomycin was prepared s y n t h e t i c a l l y and kindly donated by Dr L. Kalvoda of t h i s I n s t i t u t e * The n u e l e o s i d e analogues
were synthesized as described earlier (see Table I for references). 2[ 14 cjrhymidine was obtained from the Institute for Research and Application of Radioisotopes, Praha. The screening of nueleoside analogues for their ability of detoxicating showdomycin was performed in the following manner: 0.3 ml of aqueous solution of the analogue (about 4 all) were pipeted in duplicate into sterile test-tubes, placed on a Dubnoff shaker at 37 °C. A logarithmically growing culture of E. c o l i B or O K 305 was diluted with fresh medium to obtain a concentration of about 1 x 10r cells/ml. Three-ml portions of this fluid were then pipeted into the test tubes containing the analogue solutions, followed by the addition of showdomycin (final cone. 20/uM) to one series of the tubes, leaving the other series as controls. After shaking for 90 min at 37 °C the tubes were cooled in ice and the turbidity of the bacterial suspension was measured at 560 nm using a spectrophotometer Spectromom 203, Budapest*.
The phosphorolysis of 2'-deoxythymidine by whole c e l l s was measured as previously described . The activity of thymidine phosphorylase in cell-free extracts was determined according to Hunch-Petersen . * This experimental arrangement permitted simultaneous evaluation of toxicity and showdomycin-antagonizing ability of the analogues*. The possible chemical interaction of showdomycin with the analogues, i . e . those containing thiol groups, was minimized by the order of mixing, chosen to avoid any contact of the compounds before the start of the experiment.
49?
RESULTS
Tab. I shows that several c l a s s e s of compounds including pyrimidine as well as purine nueleoside analogues e f f i c i e n t l y antagonize the b a e t e r i o s t a t i c e f f e c t of showdomycin. The t e s t appears very s e n s i t i v e ; at the concentration r a t i o chosen most • e t i v e compounds afford nearly complete protection, p a r t i a l detoxieation being rarely observed; t o x i c i t y of some analogues such as 4-thiouridine, 5-fluorouridine or 5-hydroxyuridine s t i l l permits the d e t e c t i o n of t h e i r showdomycin-detoxicating e f f e c t , due to the f a c t that the growth arrest due to showdomycin alone i s rapid and complete.
To detect the antagonistic properties of 5-azapyrimidine nucleosidee, the s t r a i n OK 305, d e f i c i e n t in cytidine deaminase, was used with advantage. Since E. c o l i lacks deoxycytidine kinase , the only way of 2'-deoxycytidine entry into the c e l l s i s via deamination to deoxyuridine, followed by phosphoroly t i c cleavage or transdeoxyribosylation. In analogy with 2'-deoxyc y t i d i n e , 2*-deoxy-5-azacytidine cannot enter the c e l l s lacking (deoxy)cytidine deaminase and i s consequently non-toxic in this s t r a i n . In s p i t e of t h a t , we found that this compound affords e x c e l l e n t protection against showdomycin. Actual uptake of the antagonist by the c e l l s i s not e s s e n t i a l for the protective e f f e c t and the competition apparently takes place at nucleoside--binding s i t e s on the surface of the c e l l s .
Since the uptake of 5-azapyrimidine nucleosides i s dependent on the same nueleoside-transporting system as that of showdomycin * we may expect that the same analogues should the density of the bacterial culture was 3 x 10 cell6/ml.
antagonize the b a c t e r i o s t a t i e e f f e c t s of both i n h i b i t o r s . Therefore, s e l e c t e d active compounda were tested for t h e i r 5-azacytidine--detoxicating a b i l i t y , t h i s time with wild-type s t r a i n E . c o l i B. I t may be seen (Tab. I) that t h i s t e s t was much l e s s s e n s it i v e than that
As shown previously, the rate of 2'-deoxythymidine phosphorolysis by the whole cells of E. coli is determined by the activity of nutleoeide-transporting system . Therefore, selected showdomycin antagonists as well as some inactive compounds were tested for their capability of inhibiting thymidine phosphorolysis both in the whole cells and in cell-free extracts. As shown in Tab. I l l , there is a good agreement between the showdomycin-detoxicating effeot and in vivo inhibition of thyaidine phosphorolysis. Even the strongest in vivo inhibitors of this reaction are inert in cell-free system, which indicates that the inhibition of thymidine phosphorylase i t s e l f cannot be responsible for in vivo inhibition observed. The easy and complete detoxication of showdomycin is apparently dut to th* fact that the affinity of this antibiotic for the nucleoside-binding sites i s relatively low. For the inhibition of thymidine phosphorolysis in vivo by showdomycin K«/Ki is equal 0.24; for the inhibition with 5-azacytidine, this ratio has been found equal to 3.5. Therefore 5-azacytidin* has about 15-times larger affinity for the binding sites than showdomycin, and the inhibitory effect of the former is therefore much more difficult to counteract. It is noteworthy that the inhibition by showdomyein has a competitive character, indicating that no irreversible inactivation of the nucleoside--binding s i t e s is taking place. According to Roy-Burman et al, , the bacteriostatic activity of showdomycin is due to its blocking the transport of glucose and other essential nutrients, presumably by reacting with thiol groups of the respective transporting system. Therefore it is surprising that showdomycin does not irreversibly inactivate the nucleoside-binding site in spite of interaating with i t . It seems that reactive thiol groups do not participate in determining the structure of v .he active sit* of the nucleoside-binding protein.
Lineweaver-Burk plots have shown that the Inhibition with 2 ' --chloro-2'-deoxy-5-methyluridine and with showdomycin has eomp e t i t i v e character4
The results presented here define structural requirements or the interaction of nucleoside analogues with nucleoside--binding s i t e s . On the other hand, the set of inhibitors aircovered may be useful.for characterising the properties of the binding sites themselves. Differential inhibition of constitutive and indacible binding sites of E. coli will be described in subsequent paper . * Th* showdomycin-detoxicating ability of 5'-pyrimidin-2-ylmer«apto-2' t 5'-did*oxyuridin* and 5'-pyrimidin-2-ylmercapto-2',5-
